Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Free Cash Flow for 8 consecutive years, with -$73.6 million as the latest value for Q1 2026.

  • Quarterly Free Cash Flow fell 18.19% to -$73.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$274.8 million through Feb 2026, down 43.37% year-over-year, with the annual reading at -$263.5 million for FY2025, 51.22% down from the prior year.
  • Free Cash Flow for Q1 2026 was -$73.6 million at Nurix Therapeutics, up from -$79.7 million in the prior quarter.
  • The five-year high for Free Cash Flow was $19.3 million in Q4 2023, with the low at -$79.7 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$44.8 million, with a median of -$44.8 million recorded in 2022.
  • The sharpest move saw Free Cash Flow crashed 721.87% in 2022, then surged 165.24% in 2023.
  • Over 5 years, Free Cash Flow stood at -$29.6 million in 2022, then surged by 165.24% to $19.3 million in 2023, then tumbled by 323.48% to -$43.2 million in 2024, then tumbled by 84.41% to -$79.7 million in 2025, then grew by 7.65% to -$73.6 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$73.6 million, -$79.7 million, and -$58.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.